Bringing together the minds that are creating the future of health.

BICO partnership conference

Get your free ticket
Bringing together the minds that are creating the future of health.

BICO partnership conference

Get your free ticket

The Bio Convergence company

What is Bio Convergence?
About us
Bico by the numbers - Q2

Future. Forward. Fast

  • Net sales Q2 2021
    0 MUSD
  • Organic growth Q2 2021
    0 %
  • Employees
    0 +
  • Instruments in the field
    0 +
  • Publications
    0 +
  • Countries
    0 +

Trusted by
industry leaders

grey-lor
grey-johnson-johnson
grey-logo-karolinska-institutet
grey-astra_c
grey-harvard-1
grey-merck
grey-roche2
grey-amgen
grey-mit_s
grey-shiseido
grey-novaratis
grey-3M
grey-genetech
grey-bristol myers
grey-celgene
grey-takeda
grey-novo nordisk
grey-boehringer-ingelheim

Customer spotlights

Get to know the trailblazers changing future of health with our products and technologies.

Explore all →

A gateway to personalized medicine
Learn more
On-demand Bioprinted Patient-specific Heart Tissue
Learn more
COVID-19 monitoring
Learn more
Printing vascularized skin
Learn more
Water quality analysis​
Learn more

Business areas

Bioprinting
Biosciences
Bioautomation

Revolutionizing Science

Our products are used in more than 2,000 laboratories including the world’s top 20 leading pharmaceutical companies, in more than 65 countries and have been cited in more than 9,000 publications.

Making the seemingly impossible, possible

Focusing on bioprinting, multiomics, cell line development and diagnostics, we enable researchers to grow cells in 3D environments, conduct high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries.

Revolutionizing Science

Our products are used in more than 2,000 laboratories including the world’s top 20 leading pharmaceutical companies, in more than 65 countries and have been cited in more than 9,000 publications.

Making the seemingly impossible, possible

Focusing on bioprinting, multiomics, cell line development and diagnostics, we enable researchers to grow cells in 3D environments, conduct high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries.
Message from the CEO

Unleashing the power of Bio Convergence

Erik Gatenholm, CEO at BICO, decided to change the group company name to better reflect the strategic bio convergence agenda and emphasize that the company comprises several subsidiaries divided into three business areas. Now, the journey begins to build a world-famous brand.

"We have always challenged and developed the industry. We will continue to do this in a new context since the new name releases even better opportunities to communicate our offering, our plans going forward, and how we contribute to create the health of the future.

Erik Gatenholm, CEO, BICO
Message from the CEO

Unleashing the power of Bio Convergence

Erik Gatenholm, CEO at BICO, decided to change the group company name to better reflect the strategic bio convergence agenda and emphasize that the company comprises several subsidiaries divided into three business areas. Now, the journey begins to build a world-famous brand.

"We have always challenged and developed the industry. We will continue to do this in a new context since the new name releases even better opportunities to communicate our offering, our plans going forward, and how we contribute to create the health of the future.

Erik Gatenholm, CEO, BICO

press releases

October 22, 2021BICO has been awarded the Swedish Government’s Award Exporter of the Year 2021
October 19, 2021CYTENA launches C.STATION, a fully automated platform for stable cell line development to streamline production of antibody and gene therapies
October 15, 2021BICO completes the acquisition of QInstruments
October 15, 2021BICO has been nominated for the Swedish Government’s Export Success of the Year 2021 Award
October 14, 2021BICO strengthens IP Portfolio with Patents in the United States and Sweden for 3D bioprinting of Temperature Sensitive Bioinks
October 8, 2021RegulatoryNomination Committee for BICO Group AB in preparation for the 2022 Annual General Meeting
October 8, 2021RegulatoryBICO has carried out a directed share issue of SEK two billion
October 7, 2021RegulatoryBICO announces intention to carry out a directed issue of approximately SEK two billion
October 1, 2021RegulatoryBICO has entered into an agreement to acquire QInstruments, a market leader in advanced sample preparation automation for biomedical and life science research and clinical diagnostics.
September 30, 2021RegulatoryBICO announces an increase in number of shares and votes
September 21, 2021BICO Launches 3D Bioprinting contract research offering from CELLINK, MatTek and Visikol
September 15, 2021BICO has acquired HUREL micro liver technologies to offer the market's most comprehensive liver in vitro services
September 7, 2021BICO welcomes Erica Bell as Chief People Officer as company nears 1,000 employees globally
August 27, 2021BICO has acquired Advanced BioMatrix, an innovative company focused on 3D applications, to, together, ensure a market leading portfolio of bioinks and reagents
August 23, 2021DISPENDIX welcomes Petros Apostolopoulos as new CEO to strengthen position as leading liquid handling and lab automation company
August 18, 2021Introducing BICO: The Global Leader in the Bio Convergence Revolution
August 18, 2021RegulatoryInterim report January-June 2021: Increased net sales of 628% driven by M&A and organic growth of 95% and positive EBITDA in Q2.
August 13, 2021Change of name and short name (ticker) for shares in CELLINK AB (publ)
August 12, 2021The name change has been registered: CELLINK AB (publ) new name is BICO Group AB (publ)
August 12, 2021Invitation to earnings call for interim report January-June 2021
August 6, 2021RegulatoryBulletin from Extraordinary General Meeting in CELLINK AB (publ)
July 30, 2021RegulatoryCELLINK announces an increase in number of shares and votes
July 19, 2021CELLINK launches the S.NEST, a high-throughput microbioreactor with real-time monitoring to ensure maximum cell growth and streamlined workflows
July 7, 2021CELLINK has initiated the process of changing name to BICO
July 7, 2021RegulatoryNotice of Extraordinary General Meeting of CELLINK AB (publ)
July 6, 2021Visikol partners with MatTek to leverage their advanced cell culture models in its suite of drug discovery services
June 30, 2021CELLINK completes the acquisition of Discover Echo
June 30, 2021CELLINK has been granted its first patent of robotic systems for personalized and automated aesthetic medical procedures
June 30, 2021RegulatoryCELLINK announces an increase in number of shares and votes
June 29, 2021CELLINK has been granted a patent for "Cellulose Nanofibrillar Bioink for 3D Bioprinting for Cell Culturing, Tissue Engineering and Regenerative Medicine Applications" from European Patent Office
June 26, 2021RegulatoryCELLINK has entered into an agreement to acquire Discover Echo Inc., an innovative and revolutionary microscopy company
June 23, 2021CELLINKs EpiDerm ™ skin model has been approved by the OECD as a stand-alone in-vitro test method for phototoxicity
May 31, 2021CELLINK completes the acquisition of Nanoscribe
May 24, 2021CELLINK Bioprinting moves to Entré Kallebäck
May 20, 2021CELLINK has acquired Visikol, a contract research services company focused on advanced imaging, 3D cell culture assays and digital pathology
May 19, 2021RegulatoryCELLINK has entered into an agreement to acquire Nanoscribe, a market leading 3D bioprinting company based on Two-Photon Polymerization technology
May 12, 2021RegulatoryInterim report January-March 2021: High organic growth, strengthened gross margin, and strategic acquisitions
April 30, 2021RegulatoryCELLINK announces an increase in number of shares and votes
April 26, 2021RegulatoryBulletin from Annual General Meeting in CELLINK AB (publ)
April 14, 2021CELLINK receives the prestigious gold award for the BIO X6 and wins two design excellence awards for the C.WASH and UP.SIGHT at the iF Design Awards 2021.
April 6, 2021CELLINK and UPM Biomedicals has formed a collaboration for ground-breaking 3D bioprinting developments
March 31, 2021Invitation to CELLINKs digital Capital Markets Day on May 12, 2021 with focus on the bioconvergence agenda
March 31, 2021RegulatoryCELLINK announces an increase in number of shares and votes
March 26, 2021RegulatoryNotice of Annual General Meeting of CELLINK AB (publ)
March 23, 2021BIO X6 wins prestigious Red Dot Design Award for outstanding design quality
March 22, 2021CELLINK completes the acquisition of MatTek Corporation
March 17, 2021RegulatoryCELLINK publishes Annual Report 2019/2020
March 15, 2021CELLINK launches the BIO MDX Series , a scaled-up revolution in biomedical manufacturing
March 12, 2021RegulatoryCELLINK AB announces the completion of the offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an overall amount of SEK 3.0 billion
March 11, 2021RegulatoryCellink AB announces an offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an expected amount of SEK 2.75 billion
Read more

FINANCIAL REPORTS

Annual report 2019/2020
Annual report 2018/2019
Annual Report 2017/2018
Annual Report 2016/2017 (SWE)
Annual report 2016 (SWE)

Calendar

November 10, 2021Q3 report 2021
February 23, 2022Year-end report 2021
March 16, 2022Annual report 2021
Read more

Contact us

    • Investor relations

    • Isabelle Ljunggren, Head of Communications
    • Email: il@bico.com

    • Sales

    • Visit our subsidiaries' websites to explore our product offering.

Press room

Bico-LifeTech-images-1920x1080px-45
press-erik-gatenholm-bico
press-bico-logo
Bico_Logo_RGB_Horizontal
Bico-LifeTech-images-1920x1080px-24 kopiera
Bico-LifeTech-images-1920x1080px-30
Previous
Next
Download media package